Paccioni, NiccolaRahmani, MahdiehBarcia Hernández, Emilia MaríaNegro Álvarez, María Sofía Elisa2025-10-232025-10-232022-12-20Paccione N, Rahmani M, Barcia E, Negro S. Antiparkinsonian Agents in Investigational Polymeric Micro- and Nano-Systems. Pharmaceutics 2022;15:13. https://doi.org/10.3390/pharmaceutics15010013.10.3390/pharmaceutics15010013https://hdl.handle.net/20.500.14352/125306Parkinson’s disease (PD) is a devastating neurodegenerative disease characterized by progressive destruction of dopaminergic tissue in the central nervous system (CNS). To date, there is no cure for the disease, with current pharmacological treatments aimed at controlling the symptoms. Therefore, there is an unmet need for new treatments for PD. In addition to new therapeutic options, there exists the need for improved efficiency of the existing ones, as many agents have difficulties in crossing the blood–brain barrier (BBB) to achieve therapeutic levels in the CNS or exhibit inappropriate pharmacokinetic profiles, thereby limiting their clinical benefits. To overcome these limitations, an interesting approach is the use of drug delivery systems, such as polymeric microparticles (MPs) and nanoparticles (NPs) that allow for the controlled release of the active ingredients targeting to the desired site of action, increasing the bioavailability and efficacy of treatments, as well as reducing the number of administrations and adverse effects. Here we review the polymeric micro- and nano-systems under investigation as potential new therapies for PD.engAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/review articlehttps://doi.org/10.3390/pharmaceutics15010013open access615.4Parkinson’s diseasePolymeric microparticlesPolymeric nanoparticlesNeurotrophic factorsMonoamine oxidase inhibitorsAntioxidantsDopamine agonistsCatechol-o-methyl transferase inhibitorsAlpha-synuclein-targeting agentsAnti-inflammatory agentsTecnología farmaceútica3209.08 Preparación de Medicamentos3209.03 Evaluación de Medicamentos